Drug Profile
Research programme: TAK1 kinase inhibitors - Aclaris Therapeutics
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Confluence Life Sciences
- Developer Aclaris Therapeutics
- Class Small molecules
- Mechanism of Action MAP kinase kinase kinase 7 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cryopyrin-associated periodic syndromes; Pancreatic cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Cryopyrin associated Periodic Syndromes in USA (PO)
- 08 Aug 2017 Confluence Life Sciences has been acquired by Aclaris Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Pancreatic-cancer in USA (PO)